LYVE1 and neuroblastoma: Since the cortical–neuroblastoma cells (A1G11) responded well to HA-R, even when the derivatization attenuated the efficacy as compared to resveratrol in 1% ethanol solution, HA-R should be explored further as a potential receptor-mediated therapeutic for tumors with similar levels of CD44 expression.